Nitroglycerin

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	C3H5N3O9
Molecular Weight	227.0865
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O

InChI

InChIKey=SNIOPGDIGTZGOP-UHFFFAOYSA-N

InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2

HIDE SMILES / InChI

Molecular Formula	C3H5N3O9
Molecular Weight	227.0865
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16103363 | https://www.ncbi.nlm.nih.gov/pubmed/22040938

Nitroglycerin was first invented in 1847 and has been used as an active ingredient in the manufacture of explosives, mostly dynamite. Nitroglycerin came into medical use in 1878 as as a potent vasodilator (dilation of the vascular system) to treat heart conditions, such as angina pectoris and chronic heart failure. Upon administration, nitroglycerin is converted to nitric oxide (NO) by mitochondrial aldehyde dehydrogenase. NO is a potent activator of guanylyl cyclase (GC) by heme-dependent mechanisms.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Soluble guanylate cyclase 22 Target ID: CHEMBL2111348 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdf	Activator 1410

Conditions

Condition	Modality	Highest Phase	Product
Angina 15 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8360	NITROSTAT Approved Use Acute relief of angina pectoris secondary to CAD; acute prophylactic management in situations likely to provoke angina attacks; and long-term prophylactic management of angina pectoris. Launch Date 9.4703039E11
Myocardial infarction 104 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8360	NITROGLYCERIN Approved Use Management of patients with acute myocardial infarction (MI). Nitroglycerin is one of the principal initial therapies of MI. Launch Date 3.71174408E11
Hypertension 549 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8360	NITROGLYCERIN Approved Use IV nitroglycerin is used to control BP in perioperative hypertension, especially hypertension associated with cardiovascular procedures; to control BP in patients with severe hypertension† or in hypertensive crises for the immediate reduction of BP in patients in whom such reduction is considered an emergency (hypertensive emergencies), especially those associated with coronary complications (e.g., coronary ischemia, acute coronary insufficiency, acute left ventricular failure, postoperative hypertension [especially following coronary bypass surgery]); and to produce controlled hypotension during surgical procedures. Launch Date 3.71174408E11
Heart failure 87 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8360	NITROGLYCERIN Approved Use IV nitroglycerin has been used in the management of acutely decompensated (e.g., congestive) heart failure and other low cardiac-output states. Launch Date 3.71174408E11

C_max

Value	Dose	Co-administered	Analyte	Population
1.7 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:		NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
84 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:		GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
12.3 pg × min/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:		NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3380 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:		GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
40 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:		NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
50 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:		GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1 ug/kg/min multiple, intravenous (starting) Dose: 1 ug/kg/min Route: intravenous Route: multiple Dose: 1 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 16 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	Disc. AE: Hypotension... AEs leading to discontinuation/dose reduction: Hypotension (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (severe, 1 patient) Vomiting (severe, 1 patient) Headache (severe, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
35 ug/kg/min single, intravenous Dose: 35 ug/kg/min Route: intravenous Route: single Dose: 35 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/18680075	unhealthy, 50 years (range: 19 ± 74 years) n = 105 Health Status: unhealthy Age Group: 50 years (range: 19 ± 74 years) Sex: M+F Population Size: 105 Sources: https://pubmed.ncbi.nlm.nih.gov/18680075	Disc. AE: Hemodynamic test abnormal... AEs leading to discontinuation/dose reduction: Hemodynamic test abnormal (8 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/18680075
0.6 mg/h 1 times / day multiple, transdermal Highest studied dose Dose: 0.6 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.6 mg/h, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26263283	unhealthy, 51.4 ±4.3 years n = 11 Health Status: unhealthy Condition: menopausal hot flashes Age Group: 51.4 ±4.3 years Sex: F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/26263283	Sources: https://pubmed.ncbi.nlm.nih.gov/26263283
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/110268	unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/110268	Disc. AE: Pruritic rash, Erythema edematous... AEs leading to discontinuation/dose reduction: Pruritic rash (2 patients) Erythema edematous (2 patients) Vesicular eruption (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/110268
40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021134s009lbl.pdf https://pubmed.ncbi.nlm.nih.gov/6771417	unhealthy, 80 years n = 1 Health Status: unhealthy Condition: angina pectoris Age Group: 80 years Sex: M Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021134s009lbl.pdf https://pubmed.ncbi.nlm.nih.gov/6771417	Other AEs: Methemoglobinemia... Other AEs: Methemoglobinemia (grade 5, 1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021134s009lbl.pdf https://pubmed.ncbi.nlm.nih.gov/6771417
0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	Other AEs: Headache, Lightheadedness... Other AEs: Headache (63%) Lightheadedness (6%) Hypotension (4%) Syncope (4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf
1.5 mg 2 times / day multiple, rectal Dose: 1.5 mg, 2 times / day Route: rectal Route: multiple Dose: 1.5 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf	Disc. AE: Hypotension... AEs leading to discontinuation/dose reduction: Hypotension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf
5 ug/kg 1 times / day single, subcutaneous Dose: 5 ug/kg, 1 times / day Route: subcutaneous Route: single Dose: 5 ug/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32282432	unhealthy, pediatric n = 57 Health Status: unhealthy Age Group: pediatric Population Size: 57 Sources: https://pubmed.ncbi.nlm.nih.gov/32282432	Sources: https://pubmed.ncbi.nlm.nih.gov/32282432

AEs

AE	Significance	Dose	Population
Hypotension	4 patients Disc. AE	1 ug/kg/min multiple, intravenous (starting) Dose: 1 ug/kg/min Route: intravenous Route: multiple Dose: 1 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 16 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
Headache	severe, 1 patient Disc. AE	8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
Nausea	severe, 1 patient Disc. AE	8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
Vomiting	severe, 1 patient Disc. AE	8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/9916961	pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9916961
Hemodynamic test abnormal	8 patients Disc. AE	35 ug/kg/min single, intravenous Dose: 35 ug/kg/min Route: intravenous Route: single Dose: 35 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/18680075	unhealthy, 50 years (range: 19 ± 74 years) n = 105 Health Status: unhealthy Age Group: 50 years (range: 19 ± 74 years) Sex: M+F Population Size: 105 Sources: https://pubmed.ncbi.nlm.nih.gov/18680075
Erythema edematous	2 patients Disc. AE	2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/110268	unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/110268
Pruritic rash	2 patients Disc. AE	2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/110268	unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/110268
Vesicular eruption	2 patients Disc. AE	2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/110268	unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/110268
Methemoglobinemia	grade 5, 1 patient	40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021134s009lbl.pdf https://pubmed.ncbi.nlm.nih.gov/6771417	unhealthy, 80 years n = 1 Health Status: unhealthy Condition: angina pectoris Age Group: 80 years Sex: M Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021134s009lbl.pdf https://pubmed.ncbi.nlm.nih.gov/6771417
Hypotension	4%	0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf
Syncope	4%	0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf
Lightheadedness	6%	0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf
Headache	63%	0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf
Hypotension	Disc. AE	1.5 mg 2 times / day multiple, rectal Dose: 1.5 mg, 2 times / day Route: rectal Route: multiple Dose: 1.5 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:28787	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28787
ChemicalBook	CB2145318	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2145318
ZINC	ZINC000008214625	http://zinc15.docking.org/substances/ZINC000008214625

PubMed

Title	Date	PubMed

Acute normovolemic hemodilution and nitroglycerin-induced hypotension: comparative effects on tissue oxygenation and allogeneic blood transfusion requirement in total hip arthroplasty.	1999 Aug	10526806
Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes.	2000 Aug	10958127
Coronary spastic angina induced by anticholinesterase medication for myasthenia gravis--a case report.	2000 Dec	11132996
Glyceryl trinitrate for chronic anal fissure--healing or headache? Results of a multicenter, randomized, placebo-controled, double-blind trial.	2000 Feb	10696890
Effectiveness of modified release isosorbide mononitrate affected by incorrect use.	2000 Feb 19	10678861
Audit of topical glyceryl trinitrate for treatment of fissure-in-ano.	2000 Jan	10700763
Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability.	2000 Jan 7	10625313
Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency.	2000 Jul	10971600
Acute myocardial ischemia after administration of ondansetron hydrochloride.	2000 Mar	10719974
Echocardiographic assessment of coronary blood flow velocity during controlled hypotensive anesthesia with nitroglycerin.	2000 Oct	11052440
Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm.	2000 Sep	11016328
The use of intravenous nitroglycerin in a case of spasm of the sphincter of Oddi during laparoscopic cholecystectomy.	2001 Apr	11379694
Treatment of anal fissure with glyceryl trinitrate in patients referred for surgical management.	2001 Apr	11355729
Does nitric oxide play a role in the aetiology of pre-eclampsia?	2001 Apr	11312629
Topical diltiazem ointment in the treatment of chronic anal fissure.	2001 Apr	11298624
Effects of nitrovasodilators on the human fetal-placental circulation in vitro.	2001 Apr	11286570
S-Transnitrosylation of albumin in human plasma and blood in vitro and in vivo in the rat.	2001 Apr 7	11295447
Improved analysis of brachial artery ultrasound using a novel edge-detection software system.	2001 Aug	11457812
Effects of nitric oxide donors on the contractility and prostaglandin synthesis of myometrial strips from pregnant and non-pregnant women.	2001 Feb	11293922
Cardiac natriuretic peptides--hope or hype?	2001 Feb	11286604
Acute myocardial infarction secondary to coronary vasospasm during withdrawal from industrial nitroglycerin exposure--a case report.	2001 Feb	11228088
Reduced venous responsiveness to endothelin-1 but not noradrenaline in hypertensive chronic renal failure.	2001 Feb	11158403
Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease?	2001 Feb 15	11182106
Enhanced 99Tc(m)-MIBI SPECT detection of hibernating myocardium following the use of sub-lingual nitroglycerine.	2001 Jan	11233554
Assessment of skin safety of a new glyceryl trinitrate transdermal patch. Animal and human studies.	2001 Jan	11215323
YC-1 enhances the responsiveness of tolerant vascular smooth muscle to glyceryl trinitrate.	2001 Jan	11201500
Acute congestive heart failure associated with a limited form of systemic sclerosis and primary biliary cirrhosis.	2001 Jan	11201376
Migraine with aura after administration of sublingual nitroglycerin tablets.	2001 Jan	11168608
Impaired vasodilator response to organic nitrates in isolated basilar arteries.	2001 Jan	11156558
Effect of isosorbide dinitrate on nitric oxide synthase under hypoxia.	2001 Jan	11150917
Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols.	2001 Jan	11146008
Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes.	2001 Jan	11115412
Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus.	2001 Jul	11472302
Different mechanisms of isoproterenol-induced and nitroglycerin-induced syncope during head-up tilt in patients with unexplained syncope: important role of epinephrine in nitroglycerin-induced syncope.	2001 Jul	11469429
Gender difference in age-related changes in vascular function.	2001 Jul	11454139
Pseudonormal diastolic filling unmasked with glyceryl trinitrate in patients with type 2 diabetes with poor metabolic control.	2001 Jul	11423529
Reduction of organic nitrates catalysed by xanthine oxidoreductase under anaerobic conditions.	2001 Jul 2	11420146
The effect of nitric oxide donors and L-arginine on the gastric electrolyte barrier.	2001 Jun	11453101
Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles.	2001 Jun	11376633
Nitric oxide in primary headaches.	2001 Jun	11371754
Ecstasy induced acute myocardial infarction.	2001 Jun	11359764
Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.	2001 Mar	11284996
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases.	2001 Mar	11179059
Urban-rural differences in the quality of care for medicare patients with acute myocardial infarction.	2001 Mar 12	11231708
Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria.	2001 May	11380077
Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model.	2001 May 1	11301495
[Nitrate headache in blasting work].	2001 May 15	11395995
Heart preservation with celsior solution improved by the addition of nitroglycerine.	2001 May 27	11391222
Treatment of chronic anal fissure with topical glyceryl trinitrate: a double-blind, placebo-controlled trial.	2001 May-Jun	11400799

Patents

Sample Use Guides

In Vivo Use Guide

Nitroglycerin in 5% Dextrose Injection is intended for intravenous administration using sterile equipment. It should be administered only via an infusion pump that can maintain a constant infusion rate. For treatment of acute anginal attack, one tablet of Nitrostat should be dissolved under the tongue or in the buccal pouch at the first sign of an acute anginal attack. The dose may be repeated approximately every 5 minutes, until relief is obtained. If the pain persists after a total of 3 tablets in a 15-minute period, or the pain is different than is typically experienced, prompt medical attention is recommended. Nitrostat may be used prophylactically 5 to 10 minutes prior to engaging in activities which might precipitate an acute attack.

Route of Administration: Other

In Vitro Use Guide

Vasoactivity of nitroglycerin was measured using an ex vivo assay. Mice thoracic aortae were removed, cleaned, and cut into 3-mm rings. Rings were mounted on strain gauge transducers under 1 g of resting tension, and maintained at 37°C in Krebs solution, bubbled continuously with 20% O2/5% CO2/75% N2. Rings were allowed to equilibrate for 1 h before active tension was induced with prostaglandin F2α. Application of Nitroglycerine relieve the F2α-induced strain with IC50 of 10-7 M for wt mice, and 10-5 for mtALDH-/- mice.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:45:49 UTC 2023` Edited by `admin` on `Wed Jul 05 22:45:49 UTC 2023`
Record UNII	G59M7S0WS3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Nitroglycerin

Systematic Name

English

NITRO-DUR

Brand Name

English

RECTIV

Brand Name

English

NITRO IV

Brand Name

English

GLYCERIN TRINITRATE

Systematic Name

English

NITROGLYCERIN TABLETS [JAN]

Common Name

English

DILUTED NITROGLYCERIN [USP-RS]

Common Name

English

NITROGLYCERIN [ORANGE BOOK]

Common Name

English

PROPANE-1,2,3-TRIYL TRINITRATE

Systematic Name

English

MINITRAN

Brand Name

English

GLONOINUM [HPUS]

Common Name

English

TRINITRIN

Common Name

English

NITROGLYCERIN [MI]

Common Name

English

NITORA

Common Name

English

NTG

Common Name

English

TRINITRINE

Common Name

English

NITROGLYCERIN [VANDF]

Common Name

English

NITROMIST

Brand Name

English

NITRONAL

Brand Name

English

NITROL

Brand Name

English

GONITRO

Common Name

English

GLONOINUM

Common Name

English

C01DA02

Code

English

NITROGLYCERIN [USP IMPURITY]

Common Name

English

NITROLINGUAL

Brand Name

English

TRIDIL

Brand Name

English

GLYCERYL TRINITRATE

Systematic Name

English

NITROSTAT

Brand Name

English

DILUTED NITROGLYCERIN [USP MONOGRAPH]

Common Name

English

GLYCERYL TRINITRATE [MART.]

Common Name

English

TRANSDERM-NITRO

Brand Name

English

TRINITROGLYCERIN

Systematic Name

English

NITRO-BID

Brand Name

English

1,2,3-PROPANETRIOL, TRINITRATE

Systematic Name

English

DILUTED NITROGLYCERIN

Common Name

English

GLYCEROL TRINITRATE

Systematic Name

English

Glyceryl trinitrate [WHO-DD]

Common Name

English

IMX-150

Common Name

English

NITROGLYCERIN [HSDB]

Common Name

English

GLYCERYL TRINITRATE SOLUTION [EP MONOGRAPH]

Common Name

English

1,2,3-PROPANETRIOL TRINITRATE

Systematic Name

English

Classification Tree Code System Code

WHO-VATC

QC05AE01